Pérez C, Campayo L, Navarro P, García-Bermejo L, Aller P
Instituto de Química Médica, CSIC, Madrid, Spain.
Biochem Pharmacol. 1994 Jul 5;48(1):75-82. doi: 10.1016/0006-2952(94)90225-9.
The action of two structurally related DNA intercalating agents has been studied and compared, namely 4'-(9-acridinylamino) methanesulphon-m-anisidide (amsacrine, mAMSA) and 1,4-bis(butylamino)benzo[g]phthalazine (ABP) on the cell cycle and differentiation of U-937 human promonocytic leukemia cells. mAMSA (0.1 microM) and ABP (4 microM) reduced the proliferation activity to a similar extent and caused little cell mortality. At these subcytotoxic concentrations mAMSA induced the cells to accumulate at the G2 phase of the cycle, while cycle inhibition provoked by ABP was not phase specific. In addition, mAMSA caused an increase in the cell mass while ABP provoked cell shrinkage. This was consistent with the fact that ABP considerably inhibited protein synthesis, while mAMSA did not significantly affect this activity. SDS/K+DNA precipitation assays indicated that mAMSA, but not ABP, stimulated protein-DNA covalent complex formation. Finally, it was found that mAMSA, but not ABP, elicited the expression of differentiation markers, namely nitroblue tetrazolium reduction, activation of vimentin and leukocyte integrin (CD11b/CD18 and CD11c/CD18) expression, and downregulation of c-myc expression. The DNA intercalators doxorubicin and mitoxantrone, which like mAMSA induced the cells to accumulate at the G2 phase and increased the cell mass, induced the expression of differentiation markers. In contrast, the intercalators aclarubicin and caffeine and the non-intercalator novobiocin, which produced minor alterations on cell-cycle distribution and caused cell shrinkage, did not significantly elicit differentiation. These results support the conclusion that differentiation of myeloid leukemia cells by cytostatic drugs depends on the perturbations of the cell cycle, leading to disproportionate increases in cell mass.
对两种结构相关的DNA嵌入剂的作用进行了研究和比较,即4'-(9-吖啶基氨基)甲磺基间茴香胺(安吖啶,mAMSA)和1,4-双(丁基氨基)苯并[g]酞嗪(ABP)对U-937人原单核细胞白血病细胞的细胞周期和分化的影响。mAMSA(0.1微摩尔)和ABP(4微摩尔)在相似程度上降低了增殖活性,且几乎不引起细胞死亡。在这些亚细胞毒性浓度下,mAMSA诱导细胞在细胞周期的G2期积累,而ABP引起的周期抑制不具有阶段特异性。此外,mAMSA导致细胞质量增加,而ABP引起细胞收缩。这与ABP显著抑制蛋白质合成而mAMSA对该活性无明显影响这一事实一致。SDS/K⁺DNA沉淀分析表明,mAMSA而非ABP刺激了蛋白质-DNA共价复合物的形成。最后发现,mAMSA而非ABP引发了分化标志物的表达,即硝基蓝四氮唑还原、波形蛋白激活以及白细胞整合素(CD11b/CD18和CD11c/CD18)表达,同时c-myc表达下调。与mAMSA一样能诱导细胞在G2期积累并增加细胞质量的DNA嵌入剂阿霉素和米托蒽醌,也诱导了分化标志物的表达。相比之下,对细胞周期分布产生轻微改变并导致细胞收缩的嵌入剂阿克拉霉素和咖啡因以及非嵌入剂新生霉素,并未显著引发分化。这些结果支持了以下结论:细胞抑制药物诱导髓系白血病细胞分化取决于细胞周期的扰动,导致细胞质量不成比例增加。